Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (high certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: 3. Specific ‐ cardiovascular ‐ short term · patients with schizophrenia
Beta‐blockers showed no clear difference in adverse effects: 3. Specific ‐ cardiovascular ‐ short term compared with placebo (low certainty).
1 finding from 1 review
Maternal drug adverse effects(4 hours after administration) · women with perineal pain in the early postpartum period
1 finding from 1 review
Maternal drug adverse effects (6 hours after administration) · women with perineal pain in the early postpartum period
NSAID showed no clear difference in maternal drug adverse effects(6 hours after administration) compared with placebo (low certainty).
1 finding from 1 review
Adverse effect: fatigue · people with focal epilepsy
Zonisamide probably leads to higher adverse effects: fatigue (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (long‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Topical aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Thymopentin showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
HSV vaccination showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Yellow fever vaccination showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects of long‐term use of available topical agents · HIV‐infected adults (> 13 years of age, per CDC) with one or more painful intraoral aphthous ulcers
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found